6 analysts have shared their evaluations of Pacira BioSciences (NASDAQ:PCRX) during the recent three months, expressing a mix of bullish and bearish perspectives.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 4 | 2 | 0 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 1 | 0 | 0 | 0 | 0 |
| 2M Ago | 0 | 0 | 0 | 0 | 0 |
| 3M Ago | 2 | 2 | 0 | 0 | 0 |
Insights from analysts' 12-month price targets are revealed, presenting an average target of $46.67, a high estimate of $57.00, and a low estimate of $43.00. This current average has decreased by 4.76% from the previous average price target of $49.00.
Understanding Analyst Ratings: A Comprehensive Breakdown
The perception of Pacira BioSciences by financial experts is analyzed through recent analyst actions...
Login or create a forever free account to read this news
Sign up/Log in